Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia

OBJECTIVES: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of defera...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Al-Khabori, Murtadha, Bhandari, Sunil, Al-Huneini, Mohammed, Al-Farsi, Khalil, Panjwani, Vinodh, Daar, Shahina
Format: Artigo
Jezik:Inglês
Izdano: OMJ 2013
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3628199/
https://ncbi.nlm.nih.gov/pubmed/23599881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5001/omj.2013.31
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki